<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498589</url>
  </required_header>
  <id_info>
    <org_study_id>GETAID 2006-1</org_study_id>
    <nct_id>NCT00498589</nct_id>
  </id_info>
  <brief_title>Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis</brief_title>
  <acronym>METEOR</acronym>
  <official_title>A Controlled, Randomized, Double-blind, Multicenter Study, Comparing Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  PHASE: II

        -  TYPE OF STUDY : With direct benefit

        -  DESCRIPTIVE: Multicenter, randomized, double-blind study

        -  INCLUSION CRITERIA: Steroid-dependent ulcerative colitis

        -  OBJECTIVES: To show superiority of methotrexate vs placebo in inducing steroid-free
           remission in steroid-dependent ulcerative colitis

        -  STUDY TREATMENTS: Methotrexate 1 intramuscular injection (25 mg) per week Placebo 1
           intramuscular injection per week

        -  NUMBERS OF PATIENTS: 55 patients in each group, i.e. a total of 110 patients

        -  INCLUSION PERIOD: 24 months

        -  STUDY DURATION: 36 months

        -  EVALUATION CRITERIA: Remission without steroids, immunosuppressives and without
           colectomy at 16 weeks of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a chronic inflammatory bowel disease that slightly reduces life
      expectancy, strongly reduces its quality and can lead to serious complications such as acute
      colitis, dysplasia and colon cancer. About 40'000 patients are affected in France Among them,
      15% suffer from a chronic active form that often leads to an extended steroid therapy, and
      its known side effects. Azathioprine has already proven its efficacy in this indication but
      brings a lasting remission without steroid in only 41% of the patients (1-4). What are the
      medications available for the patients who failed in maintaining a remission with
      azathioprine ? Cyclosporin is designed for severe or steroid-resistant forms. (5). The
      results of two recent studies have showed that infliximab is more efficacious than placebo in
      active UC (6, 7). Infliximab is expensive, its efficacy in steroid-dependent UC has not been
      specifically tested yet, and its tolerance on the long term remains uncertain. Methotrexate
      proved its efficacy in Crohn's disease with an intramuscular dose of 25mg/week (8). In UC a
      controlled trial has been negative with an oral dose of 12.5mg/week (9). Another study
      compared mercaptopurine, methotrexate (15mg/week) and 5-aminosalicylate in 72
      steroid-dependent patients with CD or UC (10). The remission rates obtained were 58% after 30
      weeks with methotrexate (not significantly different from 5-ASA) and 14% after 106 weeks (not
      significantly different from 5-ASA). Few data are available on the efficacy of methotrexate
      in UC, at a dose which is active in Crohn's disease (25mg intramuscular/week). Several
      uncontrolled series have been published, including 91 patients whose remission failed under
      azathioprine.

      Methotrexate is cheap and its patent has fallen in the public domain. Only institutional
      research will be able to finance a study in this new indication.

      This is a prospective, controlled, randomized, double-blind study of methotrexate with an
      intramuscular dose of 25mg/week vs placebo in patients with steroid-dependent UC.

      This multicenter study will take place under the aegis of the Therapeutic Study Group for
      Inflammatory Digestive Diseases (G.E.T.A.I.D.) and with the help of the gastroenterologists
      network of the CIC. The issue of this study is important. If the hypothesis is borne out, a
      cheap, efficacious medication will be available for chronic active UC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission without steroids, immunosuppressives and without colectomy</measure>
    <time_frame>week 16</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 IM or SC of placebo per week during 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>25 mg per week IM or SC during 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one intramuscular injection per week</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UC diagnosed according to the Lennard-Jones criteria (Appendix 1) with endoscopic
             colorectal lesions, whatever their extension may be

          -  A Mayo Disease Activity Index £ 4, with no item &gt;1 for the clinical part of the score
             and from 0 to 2 for the endoscopic part at the time of inclusion

          -  Steroid-dependence defined by at least 1 unsuccessful attempt to stop systemic steroid
             therapy during the last 12 weeks. Steroid therapy might have been completely stopped
             if it has been restarted within the last 30 days

          -  To be receiving a treatment of prednisone at a dose between 10 and 40mg, stable for at
             least 2 weeks at the time of inclusion

          -  Under an adequate contraception for male or female subjects of childbearing potential

        Exclusion Criteria:

          -  Indication to a colectomy.

          -  Alcoholism (more than 21 glasses per week for male subjects and 14 glasses per week
             for female subjects). 1 glass corresponds to 3 cl of strong alcohol, 10 cl glass of
             wine or a half pint of beer.

          -  Pregnant or breast-feeding female subjects.

          -  No efficacious contraception.

          -  NSAIDS or cotrimoxazole intake upon inclusion, or probenecid intake within 1 month
             prior to inclusion.

          -  Anti-TNFa treatment within 2 months prior to inclusion.

          -  Azathioprine, mercaptopurine, cyclosporin or thalidomide within 1 month prior to
             inclusion.

          -  Modification of mesalazine or olsalazine dosage within 1 month prior to inclusion.

          -  Chronic (broncho) pneumopathy.

          -  Renal failure (creatinaemia &gt; upper limit of normal laboratory values limit).

          -  Liver disease apart from primary sclerosing cholangitis.

          -  Unexplained rise higher than twice the normal level for transaminases, alkaline
             phosphatases and/or bilirubin.

          -  Folate level &lt; normal level.

          -  Past history of malignant condition (including leukaemia, lymphoma and myelodysplasia)
             except for baso-cellular cutaneous cancers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Carbonnel</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB - Cliniques Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand - Hôpital Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hôpital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Haut L'Eveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen - Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne - Hôpital NOrd</name>
      <address>
        <city>Saint Priest</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel aviv</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano , Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo Della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Besancon</investigator_affiliation>
    <investigator_full_name>Franck Carbonnel</investigator_full_name>
    <investigator_title>PU-PH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

